441 related articles for article (PubMed ID: 24393602)
1. Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial.
Paul C; Reich K; Gottlieb AB; Mrowietz U; Philipp S; Nakayama J; Harfst E; Guettner A; Papavassilis C;
J Eur Acad Dermatol Venereol; 2014 Dec; 28(12):1670-5. PubMed ID: 24393602
[TBL] [Abstract][Full Text] [Related]
2. Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and/or feet: subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study.
Sigurgeirsson B; Kircik L; Nemoto O; Mikazans I; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB
J Eur Acad Dermatol Venereol; 2014 Aug; 28(8):1127-9. PubMed ID: 24330415
[No Abstract] [Full Text] [Related]
3. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
Foley P; Gordon K; Griffiths CEM; Wasfi Y; Randazzo B; Song M; Li S; Shen YK; Blauvelt A
JAMA Dermatol; 2018 Jun; 154(6):676-683. PubMed ID: 29799960
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.
Leonardi C; Langley RG; Papp K; Tyring SK; Wasel N; Vender R; Unnebrink K; Gupta SR; Valdecantos WC; Bagel J
Arch Dermatol; 2011 Apr; 147(4):429-36. PubMed ID: 21173304
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
Papp KA; Langley RG; Sigurgeirsson B; Abe M; Baker DR; Konno P; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB
Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107
[TBL] [Abstract][Full Text] [Related]
6. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
Rich P; Sigurgeirsson B; Thaci D; Ortonne JP; Paul C; Schopf RE; Morita A; Roseau K; Harfst E; Guettner A; Machacek M; Papavassilis C
Br J Dermatol; 2013 Feb; 168(2):402-11. PubMed ID: 23362969
[TBL] [Abstract][Full Text] [Related]
7. Secukinumab in plaque psoriasis--results of two phase 3 trials.
Langley RG; Elewski BE; Lebwohl M; Reich K; Griffiths CE; Papp K; Puig L; Nakagawa H; Spelman L; Sigurgeirsson B; Rivas E; Tsai TF; Wasel N; Tyring S; Salko T; Hampele I; Notter M; Karpov A; Helou S; Papavassilis C; ;
N Engl J Med; 2014 Jul; 371(4):326-38. PubMed ID: 25007392
[TBL] [Abstract][Full Text] [Related]
8. Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trial.
Augustin M; Abeysinghe S; Mallya U; Qureshi A; Roskell N; McBride D; Papavassillis C; Gelfand J
J Eur Acad Dermatol Venereol; 2016 Apr; 30(4):645-9. PubMed ID: 26660143
[TBL] [Abstract][Full Text] [Related]
9. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.
Ohtsuki M; Morita A; Abe M; Takahashi H; Seko N; Karpov A; Shima T; Papavassilis C; Nakagawa H;
J Dermatol; 2014 Dec; 41(12):1039-46. PubMed ID: 25354738
[TBL] [Abstract][Full Text] [Related]
10. The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study.
Bagel J; Duffin KC; Moore A; Ferris LK; Siu K; Steadman J; Kianifard F; Nyirady J; Lebwohl M
J Am Acad Dermatol; 2017 Oct; 77(4):667-674. PubMed ID: 28780364
[TBL] [Abstract][Full Text] [Related]
11. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
[TBL] [Abstract][Full Text] [Related]
12. Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial.
Gottlieb A; Sullivan J; van Doorn M; Kubanov A; You R; Parneix A; Hugot S; Milutinovic M
J Am Acad Dermatol; 2017 Jan; 76(1):70-80. PubMed ID: 27707593
[TBL] [Abstract][Full Text] [Related]
13. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).
Blauvelt A; Prinz JC; Gottlieb AB; Kingo K; Sofen H; Ruer-Mulard M; Singh V; Pathan R; Papavassilis C; Cooper S;
Br J Dermatol; 2015 Feb; 172(2):484-93. PubMed ID: 25132411
[TBL] [Abstract][Full Text] [Related]
14. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE).
Paul C; Lacour JP; Tedremets L; Kreutzer K; Jazayeri S; Adams S; Guindon C; You R; Papavassilis C;
J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1082-90. PubMed ID: 25243910
[TBL] [Abstract][Full Text] [Related]
16. Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE).
Thaçi D; Humeniuk J; Frambach Y; Bissonnette R; Goodman JJ; Shevade S; Gong Y; Papavassilis C;
Br J Dermatol; 2015 Sep; 173(3):777-87. PubMed ID: 25823958
[TBL] [Abstract][Full Text] [Related]
17. Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study.
Bissonnette R; Poulin Y; Guenther L; Lynde CW; Bolduc C; Nigen S
J Eur Acad Dermatol Venereol; 2011 Dec; 25(12):1402-8. PubMed ID: 21349113
[TBL] [Abstract][Full Text] [Related]
18. Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial.
Lacour JP; Paul C; Jazayeri S; Papanastasiou P; Xu C; Nyirady J; Fox T; Papavassilis C
J Eur Acad Dermatol Venereol; 2017 May; 31(5):847-856. PubMed ID: 28111801
[TBL] [Abstract][Full Text] [Related]
19. Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.
Gottlieb AB; Langley RG; Philipp S; Sigurgeirsson B; Blauvelt A; Martin R; Papavassilis C; Mpofu S
J Drugs Dermatol; 2015 Aug; 14(8):821-33. PubMed ID: 26267726
[TBL] [Abstract][Full Text] [Related]
20. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
Blauvelt A; Reich K; Tsai TF; Tyring S; Vanaclocha F; Kingo K; Ziv M; Pinter A; Vender R; Hugot S; You R; Milutinovic M; Thaçi D
J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]